Sharing Insight of Business Opportunities & Future Challenges in Life Sciences & Health
Health-Holland and Invest in Holland hold network event for Dutch LSH community
The Top Sector Life Sciences & Health (LSH; Health-Holland) and Invest in Holland together hosted a network event on 12 December in Rotterdam to discuss business opportunities and future challenges in Health & Care. More than 100 business leaders, entrepreneurs, scientists and government representatives were on hand to connect and share ideas from their field of expertise.
The network event was designed to bring together both established and new LSH organizations and to provide them with an opportunity to share their perspectives on working within the Dutch LSH ecosystem.
Speakers included Carmen van Vilsteren, chair of Top Sector Life Sciences & Health; Anant Murthy, General Manager Benelux, Alnylam Pharmaceuticals; Marika Murto, General Manager Amgen Netherlands; Bert Roossien, Global Head Active Medical Devices, BSI Group; Angus Livingstone, Valorization Director, Oncode Institute; and Janny van den Eijnden, Director, hDMT (Institute for Human Organ and Disease Model Technologies).
Recognition for positive impact on Dutch economy and society
During the event three organizations active in the Dutch Life Sciences & Health sector were awarded for their contribution to the Dutch economy and society. For example, how they help to strengthen LSH clusters through innovation and technology as well as how they contribute to communities and a healthy society. The companies were nominated by LSH experts, economic regional development agencies and large cities in the Netherlands.
The winner in the category ‘well-established’ was MSD. Named ‘best newcomer’ was Alnylam Pharmaceuticals. Acknowledged as ‘most patient-centric company was imec.
The Life Sciences & Health ecosystem in the Netherlands
The Netherlands is a global hub for life sciences & health innovation. It is home to an interconnected ecosystem of LSH expertise and enterprise, from biopharma and medical technology to e-health and patient care. As the new home of the European Medicines Agency (EMA) and with more than 3,100 innovative life sciences companies, seven university medical centers and 12 internationally-oriented universities engaged in advanced biomedical research, the Netherlands is among the most well-connected life sciences communities in the world. The characteristic Dutch collaboration between science, business, government and patients is a strong catalyst for accelerating LSH innovation into practice. Furthermore, the Netherlands’ high-quality infrastructure and logistics services provide LSH companies with a springboard to the European market and beyond.
Source: Invest in Holland
